At December 31, 2007, the Company's cash, short- and long-term investments, totaled $20.4 million, compared to $17.7 million at December 31, 2006. Net cash used in operating activities in the fourth quarter of 2007 was $4.3 million. The Company continues to prudently manage expenses and cash utilization.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements
This news release contains forward-looking statements that involve
significant risks and uncertainties, including statements regarding
Vermillion's plans, objectives, expectations and intentions. These
forward-looking statements are based on Vermillion's current expectations.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for such forward-looking statements. In order to comply with the
terms of the safe harbor, Vermillion notes that a variety of factors could
cause actual results and experience to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. There are no guarantees that Vermillion will succeed in its
efforts to commercialize its diagnostic tests in 2008 or during any other
period of time. Factors that could cause actual results to materially
differ include but are not limited to: (1) uncertainty in obtaining
intellectual property protection for inventions made by Vermillion; (2)
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved